Therapeutic agent for amyotrophic lateral sclerosis (ALS)
An object of the present invention is to provide a novel medicament with which motor neuron diseases can be treated. According to the present invention, there is provided a therapeutic agent for motor neuron diseases which comprises 3-methyl-1-phenyl-2-pirazoline-5-on or physiologically acceptable salts thereof as an active ingredient.
1. A method for treating motor neuron diseases consisting essentially of administering an effective amount of 3-methyl-1-phenyl-2-pyrazoline-5-one or a physiologically acceptable salt thereof to a patient.
2. The treatment method according to claim 1 wherein the progress of motor neuron diseases is delayed.
3. The treatment method according to claim 1 wherein the motor neuron disease is amyotrophic lateral sclerosis (ALS), spinal muscle atrophy (SMA), progressive bulbar palsy, or primary lateral sclerosis (PLS).
4. The treatment method according to claim 1 wherein the motor neuron disease is amyotrophic lateral sclerosis (ALS).
5. A method for enhancing motor neurons consisting essentially of administering an effective amount of 3-methyl-1-phenyl-2-pyrazoline-5-one or a physiologically acceptable salt thereof to a patient.